Abstract-Disruption of the gut microbiota, termed gut dysbiosis, has been described in animal models of hypertension and hypertensive patients. We have shown that gut dysbiosis plays a causal role in the development of hypertension in a rat model of obstructive sleep apnea (OSA). Functional analysis of the dysbiotic microbiota in OSA demonstrates a loss of short chain fatty acid-producing bacteria. However, measurements of short chain fatty acid concentrations and testing of their role in blood pressure regulation are lacking. We hypothesized that reduced short chain fatty acids in the gut are responsible for OSA-induced hypertension. OSA significantly increased systolic blood pressure at 7 and 14 days (P<0.05), an effect that was abolished by the probiotic Clostridium butyricum or the prebiotic Hylon VII. The 16S rRNA analysis identified several short chain fatty acid-producing bacteria that were significantly increased by C butyricum and Hylon treatment. Acetate concentration in the cecum was decreased by 48% after OSA (P<0.05), an effect that was prevented by C butyricum and Hylon. C butyricum and Hylon reduced OSA-induced dysbiosis, epithelial goblet cell loss, mucus barrier thinning, and activation of brain microglia (P<0.05 for each). To examine the role of acetate in OSA-induced hypertension, we chronically infused acetate into the cecum during 2 weeks of sham or OSA. Restoring cecal acetate concentration prevented OSA-induced gut inflammation and hypertension (P<0.05). These studies identify acetate as a key player in OSA-induced hypertension. We demonstrate that various methods to increase cecal acetate concentrations are protective from the adverse effects of OSA on the microbiota, gut, brain, and blood pressure. (Hypertension.
I
n the past decade, it has become increasingly apparent that disruption of the native gut microbiota is strongly linked to a number of disease states, including metabolic disorders (obesity and diabetes mellitus), neurological diseases (stroke outcome and Alzheimer), and cardiovascular diseases (atherosclerosis and hypertension). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Evidence for the role of the gut microbiota in development of hypertension has been obtained in 4 different animal models of hypertension and to a lesser extent for hypertension in humans. [1] [2] [3] [4] 6, 15, 16 Although there is strong evidence for a role of the gut microbiota in hypertension, the mechanism how the microbiota induce hypertension is not well understood. Although circumstantial, several studies suggest that decreases in bacterial-derived short chain fatty acids (SCFAs) may have a prominent role in the onset of hypertension. [2] [3] [4] 17, 18 The majority of the SCFAs (primarily acetic, propionic, and butyric acids) in the host are produced via fermentation of dietary undigestible fibers and starches by bacteria residing in the lower gastrointestinal tract. 19 These SCFAs can affect the host through activation of G protein-coupled receptors or inhibition of histone deacetylases. [19] [20] [21] Working through either or both of these pathways, SCFAs stabilize the gut epithelial barrier, modulate cytokine secretion, alter T-lymphocyte populations, increase the protective mucus layer, and modulate antibody secretion. 19, 22 In addition to having an effect on the gut, SCFAs can influence tissues and organs beyond the gut if they gain access to the circulation. 18, 21, [23] [24] [25] We recently reported that a high-fat diet (HFD) synergizes with apnea in a rat model of obstructive sleep apnea (OSA) to elicit hypertension. 2 When the cecal and colonic contents of hypertensive rats were gavaged into rats, which were otherwise not destined for hypertension, hypertension developed during the course of 2 weeks. 2 This key experiment proved that something in the gut contents (ie, microbiota) was necessary to elicit hypertension. We found that this OSA-induced hypertension was accompanied by decreases in bacteria that November 2018 produced SCFAs. 2 Similarly, decreased SCFA-producing bacterial abundance has also been described in spontaneously hypertensive rats. 1, 4 Although these observations are suggestive, we do not know if SCFAs are actually decreased in our model of OSA-induced hypertension.
Given that a bacterially derived SCFA could have a role in the development of hypertension, we tested the hypothesis that decreases in SCFAs are responsible for hypertension in a rat model of OSA. We report that hypertension in our model is accompanied by a 48% decrease in acetate in the cecum without any significant change in butyrate or propionate. In addition, we prevented OSA-induced hypertension using highly translatable pre-and probiotic treatments that maintained normal acetate concentrations in OSA rats. To demonstrate a definitive role for decreased acetate in OSA-induced hypertension, we abolished hypertension in our model by restoring acetate levels by directly infusing acetate into the cecum through a chronically inserted cannula. To examine a potential mechanistic link between dysbiosis and hypertension, we examined the effects of OSA, pre-, and probiotics on neuroinflammation, a key component of OSA-induced hypertension. [26] [27] [28] We show that OSA increased neuroinflammation, which was prevented by pre-and probiotic treatments.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Experimental Animals
Animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals, Eighth Edition, published by the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine, Houston, TX. Eight-week-old male Long Evans rats, purchased from Charles Rivers Laboratories, were allowed to acclimate for 2 weeks with a 12-hour light (6 am-6 pm):12-hour dark (6 pm-6 am) cycle before being randomized to HFD, HFD+Hylon, or HFD+Clostridium butyricum.
Statistics
Line and bar plot data are expressed as mean±SEM. One-way ANOVA was performed followed by Tukey multiple comparison test (Figure 2C-2E ; Figure S2A and S2B in the online-only Data Supplement). Two-way ANOVA was performed followed by HolmSidak post hoc analysis when main effects were found to be significant ( Figures 4A, 4C , 4E, 5A-5E, 6B, and 6C; Figure S1B , S3A, S3B, S3D, S3E, and S4A-S4F). When analyzing blood pressure over several time points, a 2-way repeated measures ANOVA was used followed by a Holm-Sidak test for individual comparisons when appropriate (Figures 1 and 5F ). Differences were considered statistically significant if P≤0.05.
Results

C butyricum and Hylon Prevented OSA-Induced Hypertension
In HFD-fed rats, systolic blood pressure (SBP) significantly increased by 24 and 44 mm Hg after 1 and 2 weeks of OSA, respectively, as compared with sham rats ( Figure 1A ). Given that multiple animal models of hypertension exhibit a decrease in SCFA-producing bacteria, we treated sham and OSA rats with the probiotic C butyricum or the prebiotic Hylon VII. C butyricum is capable of producing both acetate and butyrate and is found in commercially available probiotic supplements. 29 Hylon VII is a resistant corn starch that serves as a substrate for bacterial fermentation and SCFA generation and has been shown to increase fecal acetate and butyrate concentrations. 30 OSA-induced hypertension was prevented by treatment with either C butyricum or Hylon VII ( Figure 1B and 1C) . Two-way repeated measures ANOVA of the 6 groups presented in Figure 1 showed no significant effect of treatment (ie, probiotic, prebiotic) on sham SBP. This indicates that probiotic and prebiotic were capable of preventing increased SBP because of OSA but did not affect SBP in normotensive sham rats (Figure 1 ).
C butyricum and Hylon Altered the Gut Microbiota Composition
Compared with normotensive controls, the microbiota has been shown to be altered in multiple models of hypertension. 1, 2, 4, 6 Microbiota transplants between normotensive and hypertensive models have demonstrated that the microbiota plays a causal role in the development of hypertension.
1,2 Therefore, we initially examined the effects of C butyricum and Hylon on the microbiota in the absence of OSA (ie, shams alone). Community richness and diversity were not different between HFD alone and HFD+C butyricum. Compared with HFD alone, HFD+Hylon significantly reduced community richness and diversity ( Figure S2A and S2B). Similarly, HFD+Hylon, but not HFD+C butyricum, showed clear separation from HFD alone in both unweighted and weighted Unifrac principal coordinate analysis ( Figure S2C ; Figure 2A ). Linear discriminant analysis effect size (LEfSe) analysis was performed to identify key taxa that characterized HFD alone versus HFD+C butyricum versus HFD+Hylon. Figure 2B shows that 9, 12, and 4 taxa were found to be characteristic of HFD alone (blue bars), HFD+C butyricum (red bars), and HFD+Hylon (orange bars), respectively. The relative abundance of taxa found to be the most characteristic (linear discriminate analysis score of >4.0; Figure 2B ) of each treatment group are presented in Figure 2C through 2E. Of particular interest, HFD alone was characterized by an increased abundance of RC4-4 and Akkermansia, as compared with HFD+C butyricum or HFD+Hylon ( Figure 2C ). Increased RC4-4 abundance has been associated with obesity. 31 Studies suggest Akkermansia is beneficial in the setting of obesity and diabetes mellitus. 32 However, increased Akkermansia abundance has been observed in patients and animal models of multiple sclerosis. 33, 34 In addition, the relative abundance of several SCFA-producing bacteria was increased with C butyricum and Hylon. For example, Clostridiales trended (P=0.08) to be increased in HFD+C butyricum while Bifidobacterium, Ruminococcus, Blautia, and Colinsella were each significantly increased in HFD+Hylon, as compared with HFD alone ( Figure 2D and 2E). In total, of the 13 genera found to be characteristic of HFD+C butyricum and HFD+Hylon, and 6 have been identified as SCFA producers in the gut ( Figure 2B ).
The effects of OSA on the gut microbiota of HFD alone, HFD+C butyricum, and HFD+Hylon are presented in Figure  S3 and Figure 3 . Measures of α and β diversity did not show significant differences because of OSA in any of the treatment groups (Figure S3A-S3C; Figure 3A ). Richness and diversity were significantly reduced in both sham and OSA of HFD+Hylon versus HFD alone and HFD+C butyricum ( Figures S3A and S3B) . Similarly, HFD+Hylon sham and OSA samples clustered separate from HFD alone and HFD+C butyricum samples in unweighted and weighted Unifrac principal coordinate analysis ( Figure S3C ; Figure 3A ). Relative abundance of the major phyla is presented in Figure 3B . OSA did not result in any significant changes in the major phyla in any of the treatment groups. HFD+Hylon treated rats showed a significant increase in Actinobacteria abundance as compared with HFD alone and HFD+C butyricum ( Figure 3B ; Figure  S3D ). The relative abundance of the phylum Verrucomicrobia was significantly greater in HFD rats than in HFD+Hylon and trended to be greater than HFD+C butyricum ( Figure 3B ; Figure S3E ). Figure 3C shows the bacterial taxa that were altered by OSA on the HFD alone, HFD+C butyricum, and HFD+Hylon according to LEfSe analysis. On HFD alone, 5 taxa were shown to be enriched in sham versus OSA (green bars) and 3 taxa enriched in OSA versus sham (red bars). C butyricum and Hylon diminished the effects of OSA on the microbiota, both in the number of taxa altered and the magnitude of the alteration. OSA had no significant effect on any taxa in HFD+Hylon-treated rats.
OSA-Induced Damage to the Gut Wall Was Reduced by C butyricum and Hylon
We next sought to examine the effects of OSA on the gut wall, with and without C butyricum and Hylon. Figure 4 demonstrates that OSA caused a significant decrease in the number of mucus-producing goblet cells in the cecum. C butyricum and Hylon prevented the loss of goblet cells in cecum after OSA ( Figure 4A and 4B). Compared with HFD alone, HFD+Hylon significantly increased cecum goblet cells independent of OSA ( Figure 4A and 4B). Because OSA decreased the number of mucus-producing goblet cells, we next examined the proximity of bacteria to the epithelial layer in cecum. Using the EUB 338 FISH (fluorescence in situ hybridization) probe to unbiasedly label bacteria, we measured the mucus barrier thickness as the distance separating luminal bacteria from the underlying epithelium. In the HFD-alone group, OSA decreased the separation of luminal bacteria from the epithelium by 30% ( Figure 4C and 4D) . Epithelium-bacteria separation was not altered by OSA in C butyricum-or Hylon-treated rats. We tested intestinal barrier function by gavaging rats with 4 kDa fluorescein isothiocyanate-dextran on day 10 of sham or OSA. We found a significant increase in plasma fluorescein isothiocyanate of HFD OSA and HFD+C butyricum OSA rats as compared with shams of the respective groups, indicating gut barrier impairment in these 2 groups ( Figure 4E ).
OSA Reduced Cecal Acetate, Which Was Prevented by C butyricum and Hylon
We next tested whether the OSA-induced changes to the microbiota led to changes in microbial metabolites that may contribute to the adverse effects of OSA on the gut and blood pressure. Microbiota analysis revealed a number of SCFA producers that were altered by OSA, C butyricum, and Hylon (Figures 2 and 3) . For this reason, we measured SCFA concentrations in cecal content and portal plasma. OSA led to a significant decrease in cecal acetate concentration in HFD rats ( Figure 5A ). C butyricum and Hylon prevented the OSAinduced decrease in cecal acetate concentration ( Figure 5A ). In addition, as compared with HFD alone, HFD+Hylon led November 2018 to a significant increase in cecal acetate and butyrate concentration, independent of OSA ( Figure 5A ; Figure S4B ). OSA did not alter cecal concentration of propionate or butyrate ( Figure S4A and S4B) . OSA did not alter acetate, propionate, or butyrate concentrations in portal plasma ( Figure 5B ; Figure  S4C and S4D). However, similar to observations in cecum, HFD+Hylon increased portal plasma butyrate concentrations independent of OSA ( Figure 5B ). 
Cecal Acetate Treatment Prevented Adverse Effects of OSA on Gut and Blood Pressure
After the observation that OSA is associated with a decrease in cecal acetate concentration, we attempted to deliver acetate to the cecum and colon through a chronic indwelling catheter. By using a chronic infusion throughout the 2 weeks of sham or OSA, we were able to elevate acetate concentrations continuously, as opposed to the acute transient increases in acetate levels that would follow gavage or drinking water administration. In addition, catheter infusion ensured delivery to the site of interest, in this case the cecum and colon. Cecal infusion of 20 µmol/(kg-min) sodium acetate or PBS vehicle began 2 days before sham or OSA and continued throughout the study. After 2 weeks of sham or OSA, OSA rats treated with PBS had a significant reduction in cecal acetate concentration ( Figure 5C ). Rats treated with cecal acetate showed an ≈2-fold increase in cecal acetate relative to sham rats receiving PBS, and there was no significant difference between sham and OSA rats treated with acetate ( Figure 5C ). There was no significant effect of OSA on portal plasma acetate concentrations in PBS-or acetate-treated rats. However, acetate infusion did significantly increase portal plasma acetate levels by ≈2-fold ( Figure S4E ). There was no significant effect of OSA or cecal acetate treatment on systemic plasma acetate concentrations ( Figure S4F ).
We next assessed the effects of OSA and acetate on inflammatory markers in the cecum wall. In PBS-treated rats, OSA led to an increase in interleukin-1α and interleukin-6 mRNA levels ( Figure 5D and 5E). Acetate infusion prevented the OSA-induced increases in interleukin-1α and interleukin-6 mRNA levels, which were not significantly different from sham rats treated with PBS ( Figure 5D and 5E). SBP was measured during the 2 weeks of sham or OSA in PBS-and acetate-treated rats. Similar to our previous findings ( Figure 1A) , OSA led to significant increases in SBP at 1 and 2 weeks in PBS-treated rats, as compared with sham rats treated with PBS ( Figure 5F ). SBP of sham rats treated with acetate was not different from sham rats treated with PBS. However, cecal acetate infusion prevented any significant changes in SBP because of OSA ( Figure 5F ).
Neuroinflammation Associated With OSA Was Prevented by C butyricum and Hylon
Neuroinflammation plays a key role in the pathogenesis of hypertension in patients and multiple animal models. In addition, shifts in the gut microbiota, such as those described with OSA (Figure 3) , have been shown to influence brain homeostasis and neuroinflammation through the microbiota-gut-brain axis. Therefore, in an effort to examine potential mechanistic links between OSA-induced gut dysbiosis and hypertension, we assessed the effects of OSA, C butyricum, and Hylon on Figure 6A illustrates the gating strategy used to measure activated microglia (CD11b + CD45 low MHCII high ) in brain by flow cytometry. We found that OSA increased activated microglia in brain by ≈3-fold ( Figure 6B ). As further evidence that the gut influences brain, we found that C butyricum and Hylon (both administered orally) prevented OSAinduced increases in activated microglia in brain. We did not observe any significant effect of OSA on T-regulatory cells in the brain of any of the treatment groups ( Figure 6C ). However, there was a significant main effect of treatment, with those rats receiving Hylon having increased T-regulatory cells as compared with HFD alone ( Figure 6C ).
Discussion
In a rat model of OSA, we have previously demonstrated that OSA alters the normal makeup of the gut microbiota. 2 Through microbiota transplant studies, we have shown that OSA-induced dysbiosis contributes to the development of hypertension in this model. 2 We and others have gone on to show that this connection between gut dysbiosis and blood pressure is not unique to OSA and in fact exists in multiple models of hypertension. 1, [4] [5] [6] 15 Furthermore, dysbiosis associated with models of hypertension are characterized by decreased abundance of SCFA-producing bacteria. [1] [2] [3] [4] [5] We hypothesized that decreases in SCFAs are responsible for hypertension in a rat model of OSA. We report that (1) OSA results in decreased cecal acetate concentration, epithelial dysfunction, increased neuroinflammation, and hypertension. (2) In OSA rats, the probiotic C butyricum and prebiotic Hylon increase cecal acetate concentration, reduce dysbiosis and epithelial damage, and prevent neuroinflammation and hypertension. (3) Cecal infusion of acetate prevents OSA-induced epithelial inflammation and hypertension. These findings demonstrate a key role for impaired acetate production in the development of OSA-induced hypertension and suggest that treatments targeted to increase microbial acetate production may prove efficacious in the treatment of hypertension.
Fiber intake has been shown to be inversely associated with the risk of cardiovascular disease and hypertension. [35] [36] [37] These dietary fibers can be fermented by bacteria residing in the gut to generate SCFAs. Studies from our laboratory and others have demonstrated that the relative abundance of many SCFA-producing bacteria is reduced in animal models of hypertension. 1, 2, 4, 5, 15 In addition, the relative abundance of several SCFA-producing bacteria, including Coprococcus, Blautia, and Roseburia, was shown to be lower in prehypertensive and hypertensive patients relative to healthy controls. 16 In the current study, we show that C butyricum and Hylon treatment significantly increase the relative abundance of numerous SCFA-producing genera, including Parabacteroides, Roseburia, Clostridium, Bifidobacterium, Ruminococcus, and Blautia. In addition, Hylon and C butyricum treatment during the 2 weeks of sham or apnea reduce the effects of OSA on altering the microbiota. LEfSe analysis, to identify taxa altered by OSA, showed 8 taxa that were significantly different between sham and OSA with HFD alone. However, only 2 taxa were different between sham and OSA in HFD+C butyricum, and no significant differences were observed between sham and OSA in HFD+Hylon-treated rats. We conclude that HFD+C butyricum-and HFD+Hylon-treated rats had a more stable microbiota when subjected to OSA than HFD alone. Thus, these treatments prevented the decrease in SCFA-producing bacteria to potentially maintain levels of cecal acetate.
SCFAs serve as the main energy source for epithelial cells and have many beneficial effects, including improving barrier function and reducing mucosal inflammation. 25 We found that OSA significantly reduces acetate, but not propionate or butyrate, concentrations in the cecum. C butyricum and Hylon prevented the decrease in acetate concentration because of OSA. Studies by Pluznick et al 24 have demonstrated that activation of the G protein-coupled receptors olfactory receptor 78 and Gpr41 (G protein-coupled receptor 41), which bind acetate and propionate, have pressor and antipressor effects, respectively. These effects have largely been attributed to effects on the vasculature and kidney. Because we did not observe any changes in SCFA concentrations in plasma after OSA, we examined the possibility that decreased acetate concentrations in the cecum were having localized effects on the epithelium. The number of mucus-producing goblet cells and mucus barrier thickness is reduced after OSA, and this is prevented with Hylon and C butyricum treatment. Similarly, goblet cells in the colon are reduced in SHR (spontaneously hypertensive rat) and AngII (angiotensin II) rat models of hypertension. 5 SHR and AngII rats also exhibit significant increases in gut permeability. 5 We found OSA rats to have modest, albeit significant, increases in gut permeability. However, the effects of OSA on permeability are not improved by C butyricum, and a trend for increased permeability still exists with Hylontreated OSA rats. These findings suggest that impaired barrier function alone may not be sufficient to induce hypertension. Because C butyricum and Hylon shifted the microbial makeup, it is possible that barrier disruption and the presence of select microbial members are both required to lead to hypertension.
Hylon and C butyricum treatment increased cecal acetate concentrations but also altered the microbiota. In addition, sucrose, which can increase gut permeability, was eliminated from the HFD+Hylon diet to maintain a similar caloric density. 38 These secondary effects of our treatments made it difficult to precisely understand the mechanism by which benefits on gut epithelium and SBP occur. To precisely address the role of acetate, we chronically infused acetate into the cecum to elevate acetate concentrations and prevent the decrease in acetate because of OSA. Cecal acetate infusion prevened OSA-induced epithelial inflammation and hypertension. In line with our findings, previous studies have shown that acetate in the drinking water reduced blood pressure in deoxycorticosterone acetate salt-treated mice. 15 Although further studies are needed to fully understand the protective effects of acetate, our findings support the idea that the primary site of action is in the gut because portal and systemic acetate concentrations are not decreased with OSA. Acetate in the gut could signal via SCFA receptors on enteric neurons to the brain resulting in blood pressure changes.
We have previously proposed the hypothesis that OSAinduced hypertension involves neuroinflammation that originates from the gut. 3 In support of this hypothesis, we find that OSA increases activated microglia in brain, and this is prevented by C butyricum and Hylon treatment. Further studies are required to understand the mechanistic links between gut dysbiosis and neuroinflammation, but there is mounting evidence that communication between these 2 sites exist. This could involve (1) breakdown of the gut barrier allowing bacteria or immunogenic molecules access to the systemic circulation and potentially the brain, (2) activation of immune cells in the gut that migrate to brain, (3) microbial metabolites in the systemic circulation acting on the brain, (4) signaling through the enteric and central nervous system (as described above with acetate), or (5) yet unidentified mechanism of gut-to-brain signaling.
Perspectives
Growing evidence demonstrates that gut dysbiosis can play a causal role in the development of hypertension. This is supported by data from several animal models and humans. Using a model of OSA-induced hypertension, we demonstrate gut dysbiosis that is associated with gut wall pathology and neuroinflammation. Understanding of the mechanistic links between gut dysbiosis and hypertension is lacking. We provide evidence of decreased acetate production by the dysbiotic OSA microbiota. Finally, we demonstrate that various methods to maintain cecal acetate concentrations prevent the adverse effects of OSA on the gut, brain, and blood pressure. These studies identify acetate as a key player in OSA-induced hypertension. Treatment strategies to maintain a healthy gut microbiota (ie, diet, pre-, or probiotics) may prove effective in the prevention and treatment of hypertension.
